What is the virological support for reduced drug regimens?
|
|
- Francis Miles
- 6 years ago
- Views:
Transcription
1 What is the virological support for reduced drug regimens? Pr Anne-Genevieve Marcelin Pitié-Salpêtrière Hospital UMR 1136 University Pierre et Marie Curie Paris, France
2 Disclosure of Personal and Commercial Support & Handling of Bias AG Marcelin has no commercial interests. AG Marcelin has received travel grants, honoraria, and study grants from various pharmaceutical companies including Gilead Sciences, Merck-Sharp & Dohme-Chibret, Janssen- Cilag and ViiV Healthcare. AG Marcelin prepared the content of this presentation using his own material with no commercial input. AG Marcelin may discuss cases and circumstance when drugs are used off label; this is his own personal clinical experience. For the proper use of medications, please review the Product Monographs.
3 Current recommendations HIV infection is deleterious starting in the very first days following infection No current strategy for HIV cure HIV has to be controlled with life long ART 3-drugs combination is still recommended for all patients starting treatment Recent guidelines provide some recommendations for simplification in virologically suppressed patients
4 1987 AZT monotherapy B.A Larder et al ; Nature NRTI dual therapy NRTI + PI B.A Larder et al ; Science 1989
5 Pressure Drug A Pressure Drugs A + B WT virus virus resistant to drug A virus resistant to drug B virus resistant to drug C virus resistant to drugs A + B Drugs. A + B + C = 0 Prob. 1 virus resistant to drug A 1/ to (10-4 to 10-5 ) Prob. 1 virus resistant to drug B 1/ to (10-4 to 10-5 ) Prob. 1 virus resistant to drugs A+B 10-4 /10-5 x 10-4 /10-5 = 10-8 to Prob. 1 virus resistant to drug C 1/ to (10-4 to 10-5 ) Probability 1 virus resistant to drugs A + B + C = 1/10-12 to <<< 10 9 to of new viruses/day
6 Do we still need 3 ARV to achieve viral suppression? Patients are initiated at much earlier stages ( ): shift in CD4: 200 to 405 cells/mm 3 HIV VL: 5 to 4.58 log 10 cps/ml Need for evaluation of lighter antiretroviral regimens, i.e. dual or single ARV combinations with potential benefits reduced toxicity better tolerability less resistance class-sparing lower costs Rather than triple therapy for all, the new dogma should become ART and lifelong viral suppression for all
7 Ideal candidates High antiviral potency High robustness in term of genetic barrier to resistance Favorable pharmacokinetics properties (minimal inter and intra variability)
8 Ideal candidates High antiviral potency High robustness in term of genetic barrier to resistance Favorable pharmacokinetics properties (minimal inter and intra variability)
9 Multi-step inhibition explains HIV-1 protease inhibitor pharmacodynamics and resistance (1) (2) (3) these immature virions produced in the presence of PIs are incapable of efficiently completing entry (1), reverse transcription (2), and post reverse transcription steps (3) At clinical concentrations, the entry inhibition by PIs is a major component of their overall inhibitory potential PIs act like multiple drugs in one S.Alireza Rabi et al; J.Clin. Invest. 2013
10 Change from BL in HIV RNA (log 10 ) 50mg QD 400mg BID 50mg QD + RTV 50mg QD mg QD 900mg BID 750mg QD 200mg QD 100mg BID 400mg BID + RTV 300mg BID 150 mg BID 300mg BID POTENCY: ARTs in MONOTHERAPY INSTI PI mg BID Min S. AIDS DeJesus E. J Acquir Immune Defic Syndr 2006 ; 43: Markowitz et al. JAIDS Volume 43(5) 15 December 2006 pp Gallant JE et al. JAIDS Goebel et al. AIDS 2006, 20: Sankatsing et al. AIDS 2003, 17: Fätkenheuer G, et al. IAS Abstract WESS ** Approved dose for etravirine is 200mg BID 8. Adkins et al. Drugs 1998, 56( 6): Kilby JM. AIDS Res Hum Retroviruses 2002; 18: Murphy RL. AIDS 2001;15:F1-F Fätkenheuer G et al. Nat Med 2005 Nov; 11: Eron JJ, N Engl J Med 1995, 333:
11 Clinical trials in naive patients : INI vs EFV and INI vs IP/r INI vs EFV ATV/r DRV/r RAL STARTMRK RAL EFV ACTG A5257 RAL > ATV/r & DRV/r EVG/co GS-US EVG/co EFV GS-US EVG/co ATV/r WAVES EVG/co > ATV/r DTG SINGLE DTG > EFV* ARIA DTG > ATV/r FLAMINGO DTG > DRV/r : Non-inferiority ; > : Superiority ; * DTG/ABC/3TC > EFV/TDF/FTC Références en fin de présentation
12 Ideal candidates High antiviral potency High robustness in terms of genetic barrier to resistance Favorable pharmacokinetics properties (minimal inter and intra variability)
13 PI Resistance Rare at VF in First-line Studies of Boosted PIs Study n PI Wk Genotypes Major PI Mutations CASTLE [1] ATV/RTV LPV/RTV ACTG 5202 [2] ATV/RTV Study 103 [3] 355 ATV/RTV 144 NR 0 ARTEMIS [4] DRV/RTV LPV/RTV FLAMINGO [5] 242 DRV/RTV 48 NR 0 ACTG 5257 [6] ATV/RTV DRV/RTV Among 4303 pts in these trials, only 2 pts developed major PI mutations at initial VF 1. Molina JM, et al. Lancet. 2008;372: Daar ES, et al. Ann Intern Med. 2011;154: Clumeck N, et al. EACS Abstract LBPS7/2. 4. Mills A, et al. AIDS. 2009;23: Clotet B, et al. Lancet. 2014;[Epub ahead of print]. 6. Landovitz R, et al. CROI Abstract 85.
14 Virologic robustness of DTG Long dissociative half life from integrase (71h) High inhibitory quotient (x19) High virologic potency (-2,46 log in monotherapy) No resistance mutations (INTI and INSTI) in any randomised clinical trials in naive or suppressed patients treated by triple combination Hightower KE, et al. Antimicrob Agents Chemother 2011;5: Song I, et al. IWCP Résumé O07 Elliot E, et al. IWCPHIV Abstract 13 Min S, et al. AIDS 2011;25: Raffi F et al. Lancet Infect Dis 2013;13: Walmsley S et al. J Acquir Immune Defic Syndr 2015 ViiV data on file (SINGLE 144-week clinical study report) Clotet B et al. Lancet 2014;383: Molina JM et al. Lancet 2015 Orrell et al. AIDS 2016; Durban, South Africa. Slides THAB0205LB. Trottier B, et al. ICAAC Oral presentation Llibre et al. CROI 2017; Seattle, WA. Abstract 2421.
15 Monotherapy
16 Virologically suppressed patients PI/r monotherapy:
17 PI/r monotherapy is possible if Clinical criteria: - High adherence - No previous CNS disorders - Nadir CD4 > 200/mm3 Virological parameters: - Previous long term virologic suppression - > at least 12 months (Guiguet et al ; AIDS 2012) - Low residual viremia - USVL < 1 cp/ml associated with low risk of VF (S Lambert-Niclot et al ; JID 2011) - Low viral DNA before switch - French guidelines: HIV DNA < 200 copies/10⁶ PBMCs and not > 1000 copies/10⁶ PBMCs - No previous failure or resistance - No HBV chronic infection
18 PI/r monotherapy is possible if Clinical criteria - High adherence - No previous CNS disorders - Nadir CD4 > 200/mm3 Virological - Previous long term virologic suppression > at least 12 months (Guiguet et al ; AIDS 2012) - Low residual viremia USVL < 1 cp/ml associated with low risk of VF (S Lambert-Niclot et al ; JID 2011) - Low viral DNA before switch French guidelines: HIV DNA < 200 copies/10⁶ PBMCs and not > 1000 copies/10⁶ PBMCs - No previous failure or resistance - No HBV chronic infection
19 Virologically suppressed patients DTG monotherapy: DOMONO: Switch to DTG Monotherapy in Virologically Suppressed Pts Not Sufficient Randomized comparison of switch to DTG 50 mg QD monotherapy vs continued baseline ART for 24 wks in virologically suppressed pts with no previous VF At Wk 24, DTG monotherapy non inferior to continued baseline ART for maintained HIV-1 RNA < 200 c/ml Study d/c early because of high VF rate after 48 wks of DTG monotherapy VF in 8/77 pts with DTG monotherapy vs 3/152 pts on combination ART in concurrent control group (P =.03) Among 6 VF cases with resistance data in DTG monotherapy group, 3/6 developed INSTI resistance (N155H, R263K, S230R, n = 1 each) Wijting I, et al. CROI Abstract 451LB.
20 Virologically suppressed patients DTG monotherapy: DOMONO: Switch to DTG Monotherapy in Virologically Suppressed Pts Not Sufficient Randomized comparison of switch to DTG 50 mg QD monotherapy vs continued baseline ART for 24 wks in virologically suppressed pts with no previous VF At Wk 24, DTG monotherapy non inferior to continued baseline ART for maintained HIV-1 RNA < 200 c/ml Study d/c early because of high VF rate after 48 wks of DTG monotherapy VF in 8/77 pts with DTG monotherapy vs 3/152 pts on combination ART in concurrent control group (P =.03) Among 6 VF cases with resistance data in DTG monotherapy group, 3/6 developed INSTI resistance (N155H, R263K, S230R, n = 1 each) Wijting I, et al. CROI Abstract 451LB.
21 Dual therapy
22 Virologically suppressed patients PI/r + 3TC DUAL-GESIDA 8014: DRV/r + 3TC Dual ART was non inferior to triple ART (TDF/FTC or ABC/3TC + DRV/r) at Wk 48» No resistance mutations in the 2 dual-therapy patients who experienced virologic failure ANRS 12286/MOBIDIP: after viral suppression with boosted PI plus NRTI in second-line ART, maintenance therapy with boosted PI plus 3TC was associated with a higher rate of success than PI monotherapy, despite the presence of M184V (96%) at first-line treatment failure Pulido F, et al. HIV Glasgow Abstract O331 Ciaffi L, Lancet HIV 2017, May 28, 2017 (Epub ahead of print)
23 M184V: reduced replicative capacity => residual activiral effect of 3TC prevents relapse of viral replication in combination with PI/r in patients already suppressed
24 Virologically suppressed patients INSTI based regimen NNRTI ANRS 163 ETRAL: switch to RAL + ETR was effective in maintaining viral suppression at Wk 48 in 165 patients» 1 pt with VF, VL = c/ml confirmed at c/ml, RAL S and ETR R : K101E, Y181C and G190A/S (see EACS PS6/4 from Soulie et al.) SWORD: switch from suppressive ART to DTG + RPV was non inferior to continued baseline ART at Wk 48» 1 pt with confirmed criteria for virologic withdrawal at Wk 36 in DTG + RPV arm had K101K/E, no INSTI resistance 3TC LAMIDOL: switch to DTG + 3TC was effective in maintaining viral suppression at Wk 48» no INSTI resistance in 3 pts with virologic failure Llibre JM, et al. CROI Abstract 44LB. Joly V, et al. CROI Abstract 458.
25 ACTG A5353: DTG + 3TC for Treatment-Naive Pts Single-arm phase II study ART-naive pts with HIV-1 RNA 1000 and < 500,000 copies/ml; no RT, INSTI, major PI resistance mutations (N = 120) Baseline: 31% HIV-1 RNA > 100,000 c/ml DTG 50 mg + 3TC 300 mg Primary Endpoint Wk 24 Virologic Outcome at Wk 24, n (%) Baseline HIV-1 RNA, copies/ml > 100,000 (n = 37) 100,000 (n = 83) Total (N = 120) Success* 33 (89) 75 (90) 108 (90) Nonsuccess 3 (8) 2 (2) 5 (4) No data 1 (3) 6 (7) 7 (6) *HIV-1 RNA < 50 copies/ml. n = 3 with PDVF; n = 1 with emergent M184V and R263R/K mixture All 3 pts had DTG levels reflective of suboptimal adherence 1. Taiwo BO, et al. IAS Abstract MOAB0107LB. 2. ClinicalTrials.gov. NCT ClinicalTrials.gov. NCT
26 Conclusions (1) Triple therapy: remains the gold standard for virologists - No resistance in case of first line VF with PI/r or DTG Drugs with high potency and high genetic barrier to resistance HIV treatment is currently evolving towards individualized therapy - To adjust chronic therapies to each individual 20% of patients are receiving dual therapies in our clinical center - We need to evaluate these strategies
27 Conclusions (2) Monotherapy - With DTG not recommended - Unacceptable risk of resistance in case of VF - Possible in virologically suppressed patients With PI/r Mainly DRV/r Despite LLV, no emergence of resistance Clinical and virological tools to identify good candidates (UsVL < 1 cp/ml, HIV DNA < 2.3 log and no resistance) Represents only 4% of patients in our clinical center
28 Conclusions (3) Dual therapy In virologically suppressed: Several options: with PI/r or DTG RT inhibitors are still needed: 3TC or NNRTI (RPV, ETR) 3TC can be substitute to 2 NRTIs even when it shouldn t work Need for more resistance data in case of VF in routine care: risk of resistance higher than with triple therapy? In naïve: Waiting for large clinical trials results: GEMINI 1 & 2 Phase IIII, DTG/3TC vs DTG/TDF/FTC (results expected in 2018) Risk of reactivation when removing 3TC/FTC/TDF in patients with chronic HBV infection
29 Virology Pitié-Salpêtrière Pr Vincent Calvez Dr Marc Wirden Dr Eve Todesco Dr Cathia Soulie Dr Thuy Nguyen Isabelle Malet Nathalie Desire Saint Antoine Pr L Morand Joubert Dr Sidonie Lambert-Niclot Dr Djeneba Fofana Infectious Diseases Pr Christine Katlama Dr Roland Tubiana Dr Marc-Antoine Valantin Rachid Agher Biostatistics Dr Philippe Flandre Pr Dominique Costagliola Dr Lambert Assoumou Maxime Grude
Reduced Drug Regimens
Dr. Jose R Arribas @jrarribas Financial disclosures JOSE R ARRIBAS Research Support: Speaker s Bureau: Viiv, Janssen, Abbvie, BMS, Gilead, MSD Board Member/Advisory Panel: Merck, Gilead Stock/Shareholder:
More informationWhat is the Virologic Support for Two-Drug Regimens?
What is the Virologic Support for Two-Drug Regimens? Daniel R. Kuritzkes, M.D. Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School Disclosures The speaker has received consulting
More informationVirological suppression and PIs. Diego Ripamonti Malattie Infettive - Bergamo
Virological suppression and PIs Diego Ripamonti Malattie Infettive - Bergamo Ritonavir-boosted PIs Boosted PIs: 3 drugs in one The intrinsic antiretroviral activity Viral suppression and high baseline
More informationCROI 2017 Review: Novel ART Strategies
Mountain West AIDS Education and Training Center CROI 2017 Review: Novel ART Strategies Brian R. Wood, MD Assistant Professor of Medicine Medical Director, Mountain West AETC ECHO Telehealth March 2, 2017
More informationAcquired INSTI Resistance. Daniel R. Kuritzkes, M.D. Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School
Acquired INSTI Resistance Daniel R. Kuritzkes, M.D. Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School Disclosures The speaker has received consulting honoraria, speaker
More informationAntiretroviral Treatment Strategies: Clinical Case Presentation
Antiretroviral Treatment Strategies: Clinical Case Presentation Department of Internal Medicine, Far Eastern Memorial Hospital, New Taipei City, Taiwan Chia-Jui, Yang M.D Disclosure No conflicts of interests.
More informationDoes Resistance Still Matter? Daniel R. Kuritzkes, M.D. Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School
Does Resistance Still Matter? Daniel R. Kuritzkes, M.D. Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School Disclosure The speaker serves as a consultant to, and has received
More informationSwitching ARV Regimens: Managing Toxicity and Improving Tolerability; Switches & Class-Sparing Approaches
Switching ARV Regimens: Managing Toxicity and Improving Tolerability; Switches & Class-Sparing Approaches Harry W. Lampiris, MD Chief, Infectious Disease Section, San Francisco VA Medical Center Professor
More informationReduced drug regimens. Josep M Llibre Infectious Diseases & Fight AIDS Fndn Univ Hosp Germans Trias i Pujol Badalona, Barcelona
Reduced drug regimens Josep M Llibre Infectious Diseases & Fight AIDS Fndn Univ Hosp Germans Trias i Pujol Badalona, Barcelona jmllibre@flsida.org 9th IAS Conference on HIV Science (IAS 2017) 23 26 July
More informationUpdate on HIV Drug Resistance. Daniel R. Kuritzkes, MD Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School
Update on HIV Drug Resistance Daniel R. Kuritzkes, MD Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School Learning Objectives Upon completion of this presentation, learners
More informationState of the ART: Integrase Inhibitors Clinical Data. Juan Berenguer Hospital General Universitario Gregorio Marañón (IiSGM) Madrid, Spain
State of the ART: Integrase Inhibitors Clinical Data Juan Berenguer Hospital General Universitario Gregorio Marañón (IiSGM) Madrid, Spain Disclosures Consulting fees and honoraria Gilead, Janssen, MSD,
More informationSwitching antiretroviral therapy to safer strategies based on integrase inhibitors. Pedro Cahn
Switching antiretroviral therapy to safer strategies based on integrase inhibitors Pedro Cahn Disclosures Research Grants: Abbvie-Merck-Richmond-ViiV Advisory boards: Merck-Sandoz-ViiV Switching in Virologically
More informationTerapia del paciente naive con un régimen de Inhibidor de la proteasa Dr. Jose R Arribas IX Curso de avances en Infección VIH y hepatitis virales
Terapia del paciente naive con un régimen de Inhibidor de la proteasa Dr. Jose R Arribas IX Curso de avances en Infección VIH y hepatitis virales clinicaloptions.com/hiv Eficacia en Ensayos Clínicos pivotales
More informationWhat is the magic number? Clinical perspective
What is the magic number? Clinical perspective Andrea De Luca Dipartimento Biotecnologie Mediche Università di Siena UOC Malattie Infettive AOU Senese Outline Regimens with reduced number of drugs Use
More informationAre the current doses of ARV correct. Richard Elion MD Associate Adjunct Clinical Professor of Medicine Johns Hopkins School of Medicine
Are the current doses of ARV correct Richard Elion MD Associate Adjunct Clinical Professor of Medicine Johns Hopkins School of Medicine Can we lower doses of HIV meds safely? Consensus Panel in Alexandria
More informationCrafting an ART Regimen for Initiation or Salvage: Are NRTI s Necessary?
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Crafting an ART Regimen for Initiation or Salvage: Are NRTI s Necessary? Brian R. Wood, MD Assistant Professor of Medicine, University of Washington Medical
More informationAntiretroviral Therapy: What to Start
FLOWED: 05-14-2015 Chicago, IL: May 18, 2015 Antiretroviral Therapy: What to Start Eric S. Daar, MD Professor of Medicine David Geffen School of Medicine University of California Los Angeles Los Angeles,
More informationMore Options, Some Opinions Initial Therapies for HIV Judith S. Currier, MD
More Options, Some Opinions Initial Therapies for HIV Judith S. Currier, MD More Options, Some Opinions: Initial Therapies for HIV Judith S. Currier, MD University of California Los Angeles Los Angeles,
More informationDr Carole Wallis, PhD Medical Director, BARC-SA Head of the Specialty Molecular Division, Lancet Laboratories, South Africa
Dr Carole Wallis, PhD Medical Director, BARC-SA Head of the Specialty Molecular Division, Lancet Laboratories, South Africa Transmitted drug resistance Resistance patterns in first-line failures in adults
More informationDebating view on less ART. Strategies under evaluation
Debating view on less ART Strategies under evaluation Andrea De Luca Dipartimento Biotecnologie Mediche Università di Siena Department of Infectious Diseases, Siena University Hospital, Italy Conflicts
More informationBon Usage des Antirétroviraux dans l Infection par le VIH
Bon Usage des Antirétroviraux dans l Infection par le VIH Pr. Jean-Michel Molina CHU St Louis, Assistance Publique Hôpitaux de Paris, INSERM U941 et Université Paris 7 Diderot, France 1 Liens d Intérêt
More informationHow to best manage HIV patient?
How to best manage HIV patient? 1 2 Treatment Treatment Failure success HIV therapy = a long life therapy Why do we want to change a suppressive ART? Side effect Comorbidities Reduce drug burden How to
More informationOptimizing Clinical Utility of Integrase Inhibitors. Anton Pozniak MD FRCP
Optimizing Clinical Utility of Integrase Inhibitors Anton Pozniak MD FRCP INSTIs-Characteristics Rapid viral load decline Low rates resistance/ Transmitted Resistance Less chance of side effects Less pills,
More information2-Drug regimens in HIV Anton Pozniak MD FRCP
2-Drug regimens in HIV Anton Pozniak MD FRCP Advantages Cost Dual Therapy Toxicities of Nukes CV risk, bone, renal disease Smaller STRs Keep drugs for later etc. Dual Therapy-Talking Points - What are
More informationREASONS FOR DISCONTINUATION OF DUAL THERAPY WITH DOLUTEGRAVIR AND RILPIVIRINE
REASONS FOR DISCONTINUATION OF DUAL THERAPY WITH DOLUTEGRAVIR AND RILPIVIRINE R. Montejano, N. Stella-Ascariz, S. Garcia-Bujalance, JI. Bernardino, V. Hontañon, R. Mican, Montes M, E. Valencia, J. González,
More informationThe Integrase Inhibitor Drug Class: A Comparative Clinical Review
The Integrase Inhibitor Drug Class: A Comparative Clinical Review Ian Frank Professor of Medicine University of Pennsylvania Philadelphia, PA USA franki@pennmedicine.upenn.edu Disclosure Gilead, ViiV/GlaxoSmithKline:
More informationViiV Healthcare investor & analyst update
ViiV Healthcare investor & analyst update 15 February 2017 David Redfern, GSK Chief Strategy Officer and Chairman, ViiV Healthcare Dr. Dominique Limet, Chief Executive Officer, ViiV Healthcare Dr. John
More informationHIV Treatment Update. Anton Pozniak Consultant Physician, Director of HIV Services Chelsea and Westminster Hospital, London
HIV Treatment Update Anton Pozniak Consultant Physician, Director of HIV Services Chelsea and Westminster Hospital, London Guidelines Nuke sparing Nukes Efavirenz placement as the gold standard ARV Role
More informationCase 1 continued. Case 1 (cont) 12/8/16. MMAH Debate Panel Thursday, December 8, Case 1
MMAH Debate Panel Thursday, December 8, 2016 Case 1 HPI 55 yo man with newly diagnosed HIV initiates care in your clinic. His CD4+ cell count is 600, with HIV VL=90,000 copies/ml. He is asymptomatic at
More informationSimplified regimens: Pros and Cons
Rio de Janeiro, 2018 Simplified regimens: Pros and Cons Pedro Cahn Treatment Strategies: A long way Monotherapy Dual therapy STIs Triple therapy Non daily regimens Simplification Mega HAART Long Acting/Extended
More informationManagement of ART Failure. EACS Advanced HIV Course 2015 Dr Nicky Mackie
Management of ART Failure EACS Advanced HIV Course 2015 Dr Nicky Mackie Outline Defining treatment success Defining treatment failure Reasons for ART failure Management of ART failure Choice of second
More informationReport Back: HIV Treatment Updates
Report Back: HIV Treatment Updates Catherine Koss, MD Assistant Professor Division of HIV, Infectious Diseases, and Global Medicine Zuckerberg San Francisco General Hospital University of California, San
More informationReduced drug regimens
Reduced drug regimens Andrea De Luca MD Dipartimento di Biotecnologie Mediche, Università di Siena Department of Internal Medicine, University Hospital, Siena, Italy Conflicts of interest Research grants
More informationDRUGS IN PIPELINE. Pr JC YOMBI UCL-AIDS REFERENCE CENTRE BREACH Sept 27, 2015
DRUGS IN PIPELINE Pr JC YOMBI UCL-AIDS REFERENCE CENTRE BREACH Sept 27, 2015 N(t)RTI The Development of TAF TAF Delivers the High Potency of TDF While Minimizing Off- Target Kidney and Bone Side Effects
More informationClinical support for reduced drug regimens. David A Cooper The University of New South Wales Sydney, Australia
Clinical support for reduced drug regimens David A Cooper The University of New South Wales Sydney, Australia Clinical support for reduced drug regimens First line optimisation Virological failure New
More information2/16/2017. Management and Prevention of HIV Infection: Case Discussion. Case 1. Case 1
Management and Prevention of HIV Infection: Case Discussion Eric S. Daar, M.D. Chief, Division of HIV Medicine Harbor-UCLA Medical Center Professor of Medicine David Geffen School of Medicine at UCLA Grant
More informationHIV - Therapy Principles
HIV - Therapy Principles Manuel Battegay and Christine Katlama Basel, Switzerland and Paris, France Disclosure MB has received honoraria for advisory board participation from Gilead, MSD, Pfizer, ViiV
More informationTwo Drug Regimens Pros and Cons. Jürgen Rockstroh Department of Medicine I University Hospital Bonn, Bonn, Germany
Two Drug Regimens Pros and Cons Jürgen Rockstroh Department of Medicine I University Hospital Bonn, Bonn, Germany HIV Clinical Forum, Moscow, Russia, Friday 23 rd November 2018 Conflict of Interest: JKR
More informationThe next generation of ART regimens
The next generation of ART regimens By Gary Maartens Presented by Dirk Hagemeister Division of Clinical Pharmacology UNIVERSITY OF CAPE TOWN IYUNIVESITHI YASEKAPA UNIVERSITEIT VAN KAAPSTAD Current state
More informationQué anuncian los nuevos trials?
Qué anuncian los nuevos trials? XVII Curso Nacional VIH/SIDA Sociedad Chilena de Infectología Agosto 2014 Dr. Carlos Beltrán Hospital Barros Luco Trudeau Universidad de Santiago Grupo SidaChile El presente
More informationJosep Mallolas Hospital Clínic Barcelona
Nuevos paradigmas en la infección VIH Josep Mallolas Hospital Clínic Barcelona 1. Do you believe, I have to start ARV therapy? Incidence and Mortality of AIDS in Spain HIV and NON-AIDS complications HIV
More informationResistance to novel integrase inhibitors
Resistance to novel integrase inhibitors Dr Anne-Geneviève Marcelin Virology - Pitié-Salpêtrière Hospital INSERM U943, UPMC HIV integrase Dr Anne-Geneviève Marcelin 1 HIV Integration: A Six Step Process
More informationWhat to look for in a paper?
What to look for in a paper? D Costagliola Institut Pierre Louis d épidémiologie et de Santé Publique Sorbonne Universités, UPMC Univ Paris 06, INSERM Disclosures I have received consultancy fees, honoraria,
More informationSecond-Line Therapy NORTHWEST AIDS EDUCATION AND TRAINING CENTER
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Second-Line Therapy David Spach, MD Clinical Director, Northwest AETC Professor of Medicine, Division of Infectious Diseases University of Washington Presentation
More information11/7/2016. Antiretroviral Therapy Strategies. Learning Objectives. After attending this presentation, participants will be able to:
Antiretroviral Therapy Strategies FORMATTED: 1/14/16 Joel E. Gallant, MD, MPH Medical Director of Specialty Services Southwest CARE Center Santa Fe, New Mexico Adjunct Professor of Medicine The Johns Hopkins
More informationThe Dawn of the TLD Era
The Dawn of the TLD Era 20th September 2018 Mark Siedner Africa Health Research Institute Harvard Medical School Outline: A Primer on Dolutegravir Do we really need more HIV drugs? The case for a new first-line
More informationACTHIV 2018: A State-of-the-Science Conference for Frontline Health Professionals
ACTHIV 2018: A State-of-the-Science Conference for Frontline Health Professionals ACTHIV 2018: A State-of-the-Science Conference for Frontline Health Professionals Are You Ready? New Drugs Are on the Way!
More informationHIV Update Allegra CPD Day Program Port Elizabeth Dr L E Nojoko
HIV Update 2014 Allegra CPD Day Program Port Elizabeth 12-02-2014 Dr L E Nojoko Global estimates for adults and children 2011 People living with HIV 34.0 million [31.4 million 35.9 million] New HIV infections
More informationKimberly Adkison, 1 Lesley Kahl, 1 Elizabeth Blair, 1 Kostas Angelis, 2 Herta Crauwels, 3 Maria Nascimento, 1 Michael Aboud 1
Pharmacokinetics of Dolutegravir and Rilpivirine After Switching to the Two-Drug Regimen From an Efavirenz- or Nevirapine- Based Antiretroviral Regimen: SWORD-1 & -2 Pooled PK Analysis Kimberly Adkison,
More informationTreating HIV: When the Guidelines Don t Fit. Joel Gallant, MD, MPH. Southwest CARE Center Santa Fe, New Mexico
Treating HIV: When the Guidelines Don t Fit Joel Gallant, MD, MPH Southwest CARE Center Santa Fe, New Mexico Johns Hopkins University School of Medicine University of New Mexico School of Medicine Disclosures
More informationInvestigational Approaches to Antiretroviral Therapy
Investigational Approaches to Antiretroviral Therapy Rajesh T. Gandhi, MD Massachusetts General Hospital Professor of Medicine Harvard Medical School Boston, Massachusetts Learning Objectives After attending
More informationDolutegravir-Rilpivirine (Juluca)
Dolutegravir-Rilpivirine (Juluca) David H. Spach, MD Clinical Director, MW AETC Professor of Medicine Division of Infectious Diseases University of Washington Last Updated: November 30, 2017 ANTIRETROVIRAL
More informationPrima linea: dovremmo evitare i PI nella terapia di prima linea per i loro effetti non desiderati? Giuseppina Liuzzi
6 th INFECtivology TOday Paestum 15-16 -17 maggio 2014 Prima linea: dovremmo evitare i PI nella terapia di prima linea per i loro effetti non desiderati? Giuseppina Liuzzi Istituto Nazionale per le Malattie
More informationDisclosures. Introduction to ARV Drug Resistance New Clinicians Workshop 12/9/16. Introduction. ARS Question
Disclosures Introduction to ARV Drug Resistance New Clinicians Workshop I have no disclosures Susa Coffey, MD Division of HIV, ID and Global Medicine ARS Question Which resistance test do you order for
More informationPretreatment drug resistance and new treatment paradigms in firstline
Michelle Moorhouse October 2018 27 th International Workshop on HIV Drug Resistance and Treatment Strategies Pretreatment drug resistance and new treatment paradigms in firstline ART Disclosures/disclaimers
More informationHIV Treatment: New and Veteran Drugs Classes
HIV Treatment: New and Veteran Drugs Classes Jonathan M Schapiro, MD National Hemophilia Center Stanford University School of Medicine Rome, March 2013 Overview Many excellent antiretroviral agents are
More informationAbstract #8 15th EU Meeting on HIV & Hepatitis (7-9 June 2017)
Epidemiological study of Doravirine associated resistance mutations in HIV-1- infected treatment-naïve patients from two large databases in France and Italy Anne-Genevieve Marcelin, Maria Mercedes Santoro,
More informationDisclosures. Update on HIV Drug Therapy: A Case based Discussion. Case # 1: Dr. Grant has received grant support from BMS, Gilead, Janssen, and Viiv
Disclosures Update on HIV Drug Therapy: A Case based Discussion Dr. Grant has received grant support from BMS, Gilead, Janssen, and Viiv Philip Grant Assistant Professor Division of Infectious Diseases
More informationSINGLE. Efficacy and safety of dolutegravir (DTG) in treatment-naïve subjects
SINGLE Efficacy and safety of dolutegravir (DTG) in treatment-naïve subjects SE/HIV/0023/14 January 2014 PHASE III DTG TRIALS IN TREATMENT-NAÏVE ADULT SUBJECTS WITH HIV SINGLE 1 N=833 Phase III non-inferiority,
More informationManagement of patients with antiretroviral treatment failure: guidelines comparison
The editorial staff Management of patients with antiretroviral treatment failure: guidelines comparison A change of therapy should be considered for patients if they experience sustained rebound in viral
More informationL infettivologia del 3 millennio: AIDS ed altro
L infettivologia del 3 millennio: AIDS ed altro VI Convegno Nazionale 15-16 -17 maggio 2014 Centro Congressi Hotel Ariston Paestum (SA) Nuove molecole ad azione anti-hiv Annalisa Saracino Clinica Malattie
More informationWhat are the most promising opportunities for dose optimisation?
What are the most promising opportunities for dose optimisation? Andrew Hill Liverpool University, UK Global Financial Crisis How can we afford to treat 15-30 million people with HIV in the future? Lowering
More informationGenotypic Resistance Testing in Routine Care in South Africa:
Genotypic Resistance Testing in Routine Care in South Africa: Is the Juice Worth the Squeeze? Mark Siedner Africa Health Research Institute Harvard Medical School Conflicts of Interest^* No financial conflicts
More informationSwitching antiretroviral therapy to safer strategies based on integrase inhibitors
Switching antiretroviral therapy to safer strategies based on integrase inhibitors Dr Paddy Mallon UCD HIV Molecular Research Group UCD School of Medicine paddy.mallon@ucd.ie UCD School of Medicine & Medical
More informationFrench National survey of resistance to integrase inhibitors in a context of routine hospital care (ANRS AC11 virology network)
French National survey of resistance to integrase inhibitors in a context of routine hospital care (ANRS AC11 virology network) Marcelin AG ; Grude M; Charpentier C; Bellecave, P; Le Guen, L; Pallier,
More informationFaculty. Robert LoNigro, MD, MS SVP and Chief Clinical Officer Envolve PeopleCare Austin, TX
Learning Objectives Investigate the impact of antiretroviral therapy selection on factors that influence therapeutic effectiveness in patients with HIV, such as adherence, drug resistance, and safety.
More information2017 NSTC Annual Meeting Eric Daar April 18, 2017
Antiretroviral Therapy Update for TB Clinicians Eric S. Daar, M.D. Chief, Division of HIV Medicine Harbor-UCLA Medical Center Professor of Medicine David Geffen School of Medicine at UCLA Grants Consultant
More informationINDUCTION/MAINTENANCE Clinical Case
INDUCTION/MAINTENANCE Clinical Case Dr. Jose R Arribas @jrarribas INDUCTION/MAINTENANCE (more or less) Dr. Jose R Arribas @jrarribas Disclosures Speaker s Bureau: Viiv, Janssen, Abbvie, BMS, Gilead, MSD
More informationARVs in Development: Where do they fit?
The picture can't be displayed. ARVs in Development: Where do they fit? Daniel R. Kuritzkes, M.D. Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School Disclosures The speaker
More informationDisclosures. Introduction to ARV Drug Resistance New Clinicians Workshop. Introduction. ARS Question 12/6/2017
Disclosures Introduction to ARV Drug Resistance New Clinicians Workshop I have no disclosures Susa Coffey, MD Division of HIV, ID and Global Medicine ARS Question Which resistance test do you order for
More informationActualités en virologie Paris, le 6 juillet 2011 Journée scientifique de Solthis
Actualités en virologie Paris, le 6 juillet 2011 Journée scientifique de Solthis Pr Vincent CALVEZ MD, PhD Dpt of Virology Pitié-Salpêtrière Hospital Paris, France Transmitted Drug Resistance in Low and
More informationINTERGRASE INHIBITORS- WHAT S NEW?
INTERGRASE INHIBITORS- WHAT S NEW? Professor Margaret Johnson Royal Free London Foundation Trust October 2018 Targeting the HIV life-cycle NEW HIV VIRON MATURATION CO-RECEPTOR BINDING FUSION BUDDING CD4
More informationKiat Ruxrungtham. Professor of Medicine Chulalongkorn University, and HIV-NAT, Thai Red Cross AIDS Research Centre
Kiat Ruxrungtham Professor of Medicine Chulalongkorn University, and HIV-NAT, Thai Red Cross AIDS Research Centre www.iasusa.org; www.aidsinfo.nih.gov; www.clinicaloptions.com; www.clinicaloptions.com/hiv
More informationRESEARCH B/F/TAF in Treatment-Naïve HIV-1 and HIV-1 RNA Suppressed Switch Patients
RESEARCH B/F/TAF in Treatment-Naïve HIV-1 and HIV-1 RNA Suppressed Switch Patients Kirsten White Gilead Sciences, Inc., Foster City, CA Background Bictegravir (BIC; B) is a novel, unboosted integrase strand
More informationAntiretroviral Treatment 2014
Activity Code FM285 Antiretroviral Treatment 2014 Rajesh Gandhi, MD Masssachusetts General Hospital Disclosures: Educational grants to my institution from Janssen, Viiv, Abbott Learning Objectives Upon
More informationTDF containing ART: Efficacy and Safety. Dr Lloyd B. Mulenga Adult Infectious Diseases Centre University Teaching Hospital Lusaka, Zambia
TDF containing ART: Efficacy and Safety Dr Lloyd B. Mulenga Adult Infectious Diseases Centre University Teaching Hospital Lusaka, Zambia 1 Indications Treatment of HIV-1 in combination with other antiretroviral
More informationThe Use of Integrase Inhibitors In Latin America: From Guidelines to the Real World Ernesto Martínez B., MD Internal Medicine, Infectious Diseases
De afbeelding kan niet worden weergegeven. The Use of Integrase Inhibitors In Latin America: From Guidelines to the Real World Ernesto Martínez B., MD Internal Medicine, Infectious Diseases DISCLOSURE
More information2 nd Line Treatment and Resistance. Dr Rohit Talwani & Dr Dave Riedel 12 th June 2012
2 nd Line Treatment and Resistance Dr Rohit Talwani & Dr Dave Riedel 12 th June 2012 Overview Basics of Resistance Treatment failure Strategies to manage treatment failure Mutation Definition: A change
More informationManagement of Treatment-Experienced Patients: New Agents and Rescue Strategies. Joel E. Gallant, MD, MPH Johns Hopkins University School of Medicine
Management of Treatment-Experienced Patients: New Agents and Rescue Strategies Joel E. Gallant, MD, MPH Johns Hopkins University School of Medicine When to Modify Therapy! Studies to date show better responses
More informationDrug toxicities: Safest PIs. Michelle Moorhouse 14 Apr 2016
Drug toxicities: Safest PIs Michelle Moorhouse 14 Apr 2016 Impact of PIs on AIDS mortality CDC.gov. Epidemiology of HIV infection. Evolution of PIs http://www.clinicaloptions.com/hiv/treatment%20updates/boosted%20pis/interactive%20virtual%20presentation/slideset.aspx
More informationART: The New, The Old and The Ugly
ART: The New, The Old and The Ugly Our Current ARVS The Nucleoside/ Nucleotide Reverse Transcriptase Inhibitors (NRTIs/ NtRTIs) Abacavir Emtricitabine Lamivudine Stavudine Tenofovir Zidovudine The Non-Nucleoside
More informationAntiretroviral Therapy in 2016
Antiretroviral Therapy in 2016 Joel Gallant, MD, MPH Southwest CARE Center Santa Fe, NM University of New Mexico School of Medicine Johns Hopkins University School of Medicine Disclosures Consulting, Advisory
More informationOptimizing the treatment
PIs are the real world answer for: Optimizing the treatment Sergio Lo Caputo Malattie Infettive - Azienda Sanitaria Firenze Evolution of ARVs DARUNAVIR PI ETRAVIRINA NNRTI DOLUTEGRAVIR INI POTENZA E ALTA
More informationLê MP, 1,2 Cournil A, 3 Kouanfack C, 4 Lem S, 5 Le Gac S, 5 Delaporte E, 3 Peytavin G, 1,2 for the NAMSAL study group
Lê MP, 1,2 Cournil A, 3 Kouanfack C, 4 Lem S, 5 Le Gac S, 5 Delaporte E, 3 Peytavin G, 1,2 for the NAMSAL study group 1 AP-HP, Hopital Bichat, Pharmacology-Toxicology, Paris, France, 2 IAME, UMR 1137,
More informationAntiretroviral Therapy: Current Recommendations, New Drugs, and Novel Strategies. Joel Gallant, MD, MPH Johns Hopkins University School of Medicine
Antiretroviral Therapy: Current Recommendations, New Drugs, and Novel Strategies Joel Gallant, MD, MPH Johns Hopkins University School of Medicine Initial Regimen: DHHS Guidelines 3/27/2012 Preferred Regimens
More informationX Congreso Nacional de GESIDA Sesión Plenaria GESIDA Nuevas Modalidades de Tratamiento Antirretroviral
X Congreso Nacional de GESIDA Sesión Plenaria Nuevas Modalidades de Tratamiento Antirretroviral Dr. José M. Miró Servicio de Enfermedades Infecciosas Hospital Clínic - IDIBAPS Universidad de Barcelona
More informationDisclosures (last 12 months)
HIV Research What s in the Pipeline? Samir K. Gupta, MD, MS Division of Infectious Diseases Indiana University School of Medicine Disclosures (last 12 months) Independent research grant funding by NIH/NHLBI,
More informationInvestigational Approaches to Antiretroviral Therapy
Investigational Approaches to Antiretroviral Therapy Rajesh T. Gandhi, MD Massachusetts General Hospital Professor of Medicine Harvard Medical School Boston, Massachusetts Learning Objectives After attending
More informationThis graph displays the natural history of the HIV disease. During acute infection there is high levels of HIV RNA in plasma, and CD4 s counts
1 2 This graph displays the natural history of the HIV disease. During acute infection there is high levels of HIV RNA in plasma, and CD4 s counts decreased. This period of acute infection or serocnversion
More informationSELECTING THE BEST ART FOR EACH PATIENT
SELECTING THE BEST ART FOR EACH PATIENT Corklin R Steinhart, MD, PhD Head, Global Medical Directors ViiV Healthcare CNVX/HIVP/0025/16 5th Asian Conference on Hepatitis & AIDS 第五届亚洲肝炎与艾滋病学术会议 28-29 May
More informationCROI 2018 Report Back
CROI 2018 Report Back Monika Roy, MD MAS Assistant Professor Division of HIV, Infectious Diseases, and Global Medicine bayareaaetc.org 1 Disclosures and Conflicts of Interest Nothing to report bayareaaetc.org
More information9th IAS Conference on HIV Science (IAS 2017), July 23-26, 2017, Paris. Mark Mascolini
Maintenance With Raltegravir/Etravirine Strong at 48 Weeks in Older Adults - Efficacy of a Maintenance Strategy with Raltegravir/Etravirine : the ANRS 163 ETRAL trial 9th IAS Conference on HIV Science
More informationProfessor José Arribas
19 th Annual Conference of the British HIV Association (BHIVA) Professor José Arribas Hospital La Paz, Madrid, Spain 16-19 April 2013, Manchester Central Convention Complex Can we live without nucleosides?
More informationAntiretroviral Drugs
Antiretroviral Drugs Dr Paddy Mallon UCD HIV Molecular Research Group Associate Dean for Research and Innovation UCD School of Medicine and Medical Science paddy.mallon@ucd.ie UCD School of Medicine &
More informationSimplifying Antiretroviral Therapy Regimens: It s not so simple
Simplifying Antiretroviral Therapy Regimens: It s not so simple Jonathan Colasanti, MD, MSPH Division of Infectious Diseases Emory University School of Medicine Disclosures No Financial Disclosures Parts
More informationResistance Post Week 48 in ART-Experienced, Integrase Inhibitor-Naïve Subjects with Dolutegravir (DTG) vs. Raltegravir (RAL) in SAILING (ING111762)
Resistance Post Week 48 in ART-Experienced, Integrase Inhibitor-Naïve Subjects with Dolutegravir (DTG) vs. Raltegravir (RAL) in SAILING (ING111762) MR Underwood 1, F DeAnda 1, D Dorey 2, K Hightower 1,
More informationPr Vincent Calvez. Faculté de Médecine Sorbonne Université UMR Sorbonne Université Inserm 1136 Service de Virologie Hôpital Pitié-Salpêtrière
Pr Vincent Calvez Faculté de Médecine Sorbonne Université UMR Sorbonne Université Inserm 1136 Service de Virologie Hôpital Pitié-Salpêtrière Pretreatment HIV Drug Resistance in the START Study Using Next
More informationClinical Pharmacology Related Considerations.
Clinical Pharmacology Related Considerations. David Back University of Liverpool UK David Back University of Liverpool Disclosures Honoraria received for advisory boards and lectures from AbbVie, BMS,
More informationOptimizing therapies in HIV suppressed patients
Optimizing therapies in HIV suppressed patients Pr Christine Katlama Sorbonne University Paris VI Pitié-Salpêtrière Hospital, Paris Institut épidémiologie et de santé publique HIV and ART Where Are We
More informationComprehensive Guideline Summary
Comprehensive Guideline Summary Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents AETC NRC Slide Set Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and
More information